Tighe Reardon - 02 Jan 2024 Form 4 Insider Report for Janux Therapeutics, Inc. (JANX)

Reporting relationship: Acting Chief Financial Officer, 10%+ Owner
Issuer ticker: JANX
Reported as of: 02 Jan 2024
Net transaction value: $0
SEC form: 4
Accepted by SEC: 03 Jan 2024, 16:52:11 UTC
Prior SEC filing: 15 Nov 2023
Next SEC filing: 05 Jun 2024
Source filing: View source filing
Reporting owner signature: /s/ Maria Dobek, Attorney-in-Fact

Key filing fact

Tighe Reardon filed Form 4 for Janux Therapeutics, Inc. (JANX) on 03 Jan 2024.

Key facts

This page summarizes Tighe Reardon's Form 4 filing for Janux Therapeutics, Inc. (JANX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 03 Jan 2024, 16:52.

Change

Previous filing in this sequence was filed on 15 Nov 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

JANX transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +157,000
Change %
Price: $0.000000
Shares after: 157,000
Date: 02 Jan 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 157,000
Exercise price: $11.02
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

25% of the shares subject to the option vest on January 1, 2025 and the balance will vest in equal monthly installments thereafter over a three year period.